Medicare AdvantageCoverageLow impact
MA06.023c, Nerve Fiber Density Testing
Independence Blue Cross·Neurology, Endocrinology, Pain Management·Medical Policy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.023c for Nerve Fiber Density Testing has been reissued with an effective date of March 4, 2026. This appears to be a policy update or clarification for this specialized neurological diagnostic testing procedure.
Action Required
By March 4, 2026: Review the complete policy MA06.023c for Nerve Fiber Density Testing at the provided URL to understand specific coverage criteria and billing requirements. Update billing procedures and staff training accordingly for any Medicare Advantage patients requiring this specialized testing.